Search Results - Massimiliano Povero

  • Showing 1 - 2 results of 2
Refine Results
  1. 1
    Retifanlimab Vs Avelumab in Patients with Metastatic Merkel Cell Carcinoma: A Cost Utility Analysis in Italy

    Retifanlimab Vs Avelumab in Patients with Metastatic Merkel Cell Carcinoma: A Cost Utility Analysis in Italy by Gianni Ghetti, Camilla Porta, Massimiliano Povero

    Published 2025-03-01
    Get full text
    Article

    Save to List
    Saved in:
  2. 2
    [Pharmacoeconomic Comparison Between Dupilumab and Tralokinumab for the Treatment of Atopic Dermatitis in Italy: A Cost-per-Responder Analysis]

    [Pharmacoeconomic Comparison Between Dupilumab and Tralokinumab for the Treatment of Atopic Dermatitis in Italy: A Cost-per-Responder Analysis] by Paolo Gisondi, Andrea Chiricozzi, Marcello Pani, Massimiliano Povero, Luca Castello, Maria Paola Pedone, Kerry Noonan, Zhixiao Wang, Roberta Di Turi

    Published 2025-05-01
    Get full text
    Article

    Save to List
    Saved in:

Search Tools: